Should testosterone therapy be discontinued in a patient with an elevated hematocrit while using testosterone gel (Androgel) who is already seeing urology?

Yes, temporarily stop AndroGel now with a hematocrit of 58%

With a hematocrit of 58%, you must stop testosterone therapy immediately until the hematocrit decreases to a safe level, then reinitiate at a reduced dose. This is a clear-cut recommendation based on the most authoritative guidelines 1.

Why This Action is Mandatory

The 2018 Endocrine Society Clinical Practice Guideline explicitly states: "If hematocrit is >54%, stop therapy until hematocrit decreases to a safe level; evaluate the patient for hypoxia and sleep apnea; reinitiate therapy with a reduced dose" 1. Your patient's hematocrit of 58% significantly exceeds this threshold, making discontinuation non-negotiable.

The Rationale Behind the 54% Cutoff

• Erythrocytosis is the most common adverse effect of testosterone therapy, occurring in a dose-dependent manner 2
• Topical preparations like AndroGel have lower rates of erythrocytosis (2.8-17.9% depending on dose) compared to intramuscular injections (43.8%), but clearly still cause clinically significant elevations 2
• While no testosterone-associated thromboembolic events had been reported in early studies 2, more recent evidence suggests increased thrombotic risk with testosterone-induced erythrocytosis 3
• The FDA label for AndroGel specifically notes that elevated hemoglobin/hematocrit is a recognized lab abnormality requiring monitoring 4

Immediate Management Steps

1. Stop AndroGel immediately - do not wait for urology consultation
2. Evaluate for secondary causes of elevated hematocrit:
   • Screen for hypoxia and sleep apnea 1
   • Consider COPD or other conditions that independently raise hematocrit 2
   • Assess hydration status
3. Monitor hematocrit until it normalizes (ideally <50%)
4. When restarting therapy:
   • Use a reduced dose (if currently on 10g, reduce to 7.5g or 5g) 1
   • Consider that transdermal gels show dose-dependent erythrocytosis rates 2
   • Recheck hematocrit 3-6 months after restarting 1

Role of Therapeutic Phlebotomy

While therapeutic phlebotomy is mentioned as an option in guidelines 2, 1, recent evidence questions its safety and efficacy 3. Phlebotomy lowers tissue oxygen and depletes iron stores, potentially triggering pathways that paradoxically increase thrombotic risk 3. The primary intervention should be dose reduction or discontinuation, not phlebotomy as first-line management.

Common Pitfalls to Avoid

• Don't wait for urology input to stop the medication - this is a medical urgency requiring immediate action
• Don't restart at the same dose - the guideline explicitly requires dose reduction 1
• Don't assume the patient needs phlebotomy first - stopping testosterone and allowing natural normalization is preferred
• Don't ignore sleep apnea screening - testosterone can worsen sleep apnea, which itself raises hematocrit 2, 1

Coordination with Urology

Since the patient is already seeing urology, coordinate the restart plan with them, but do not delay stopping the medication. Urology can help determine:

• Optimal reduced dose for restart
• Alternative testosterone formulations if needed
• Long-term monitoring strategy
• Whether the patient's hypogonadism severity justifies the risks of continued therapy

The evidence is unequivocal: a hematocrit of 58% on testosterone therapy requires immediate discontinuation 1, 5.